The Babraham Research Campus is delighted to announce Taylor Vinters and Silicon Valley Bank as the latest organisations to pledge support for the Babraham Research Campus’ life-science accelerator, Accelerate@Babraham.
Accelerate@Babraham attracts additional support from Taylor Vinters and Silicon Valley Bank
Designed to support the earliest stages of new life-science ventures, via the provision of easy-access laboratory and office space together with supporting programmes of business, science, finance and entrepreneurial mentoring, Accelerate@Babraham’s inaugural programme starts later this month. Six companies are enrolled on the programme, five of which won access to the programme, along with a raft of other benefits, including £20K non-dilutive funding, via a pitching competition which took place over the summer. The winning companies are:
- Antiverse Ltd
- Kalium Diagnostics
- Oppilotech Ltd
- Qkine Ltd
- VisusNano Ltd
In addition to the above, SNPr, a spin-out of the Babraham Institute, which is developing a platform technology that enables the linking of genomic variants (SNPs) in non-coding genomic regions to their target genes, will also join the programme.
Taylor Vinters and Silicon Valley Bank will support the start-ups via a series of 1-2-1 clinics and workshops - bringing their very specific expertise and knowledge of the life science start-up sector to bear - which will be invaluable to the six start-ups as they progress through the programme. The programme begins on September 20th and will run through until mid-December.
In addition to Taylor Vinters and Silicon Valley Bank, Accelerate@Babraham is supported by five key Strategic Partners - AstraZeneca, Eli Lilly, MedImmune, One Nucleus and RxCelerate - all of which are committed to providing hands-on support via mentoring and entrepreneurial guidance, as well as being actively involved in the ongoing strategic development of the initiative.
Patrick Farrant, Senior Partner, Taylor Vinters said: “Taylor Vinters has enjoyed a close partnership with the Babraham Research Campus for over a decade. We are thrilled to be involved with Accelerate@Babraham, supporting the development of innovative science concepts and the creation of new companies – something which is a core focus of the firm.”
Nooman Haque, Managing Director, Life Sciences & Healthcare, Silicon Valley Bank added: “Silicon Valley Bank is committed to helping next-generation entrepreneurs navigate the roadmap of building a start-up. Accelerate@Babraham, as part of the wider Babraham Research Campus provides a superb starting point for fledging life science companies within the Cambridge Cluster and as such is an initiative we are very proud to support."
Dr Karolina Zapadka, Business Acceleration Manager, Accelerate@Babraham commented: “I am extremely pleased that we have been able to secure the support of both Taylor Vinters and Silicon Valley Bank. Both organisations will bring a unique and valuable perspective to the programme. They join an incredibly experienced and innovative group of founding strategic partners, all of whom are generously giving their time and expertise to support and develop the life science ventures of the future via Accelerate@Babraham.”
Image: Patrick Farrant, Snr Partner, Taylor Vinters (left) and Nooman Haque, MD, Life Sciences & Healthcare, Silicon Valley Bank,
About Babraham Research Campus
Babraham Bioscience Technologies Ltd (BBT) is responsible for the management and commercial development of the Babraham Research Campus.
The Babraham Research Campus is distinct in its co‐location of 60 bioscience companies with the Babraham Institute, a world‐renowned research organization which receives strategic funding from the Biotechnology and Biological Sciences Research Council (BBSRC).
The aim of the campus is to support UK bioscience through academic research, but also with facilities and capabilities for early-stage and growing commercial organizations. The campus provides companies laboratory and office space, networking and collaboration opportunities, together with access to outstanding scientific facilities in an ideal geographical location at the core of the Cambridge cluster.
The campus is managed and developed by BBT on behalf of the BBT shareholders, BBSRC and the Babraham Institute.
For more information please visit: www.babraham.com
The Accelerate@Babraham programme is designed to support the creation of start-up life science concepts by providing access to the facilities and capabilities at the Babraham Research Campus, mentoring, and support with business development and fund raising. The programme is supported by strategic partners, AstraZeneca, Medimmune, One Nucleus, RxCelerate and Lilly. In addition, various other professional service companies have committed to providing clinics and guidance to these early-stage opportunities.
Babraham Bioscience Technologies Ltd (BBT) is responsible for the commercial development of the Babraham Research Campus. The Babraham Research Campus is distinct in its co-location of bioscience companies with the Babraham Institute, a world-renowned research organisation. The Campus provides companies laboratory and office space together with access to outstanding scientific facilities in an ideal geographical location at the core of the Cambridge cluster.